



REAL LIFE USE OF RALTEGRAVIR: EXPERIENCE FROM HOSPITAL GUILLERMO ALMENARA, ESSALUD

Malpartida O, Pérez-Lazo G, Collins JA for the Almenara AIDS working group_EsSalud. Lima, Peru.

INTRODUCTION

*Raltegravir is the only INSTI available within the Social Security in Peru. Access to INSTIs in Peru is still limited. The main indication for its use in our institution is as part of rescue regimens. Use of raltegravir initiated in 2008 in our center.

OBJECTIVES

This study evaluates the patterns of use of raltegravir at our hospital until may 2007.

RESULTS

- Out of 1547 patients in the HIV program during the study period, we identified 155 using raltegravir (10%). Mean age at baseline (start of the raltegravir-based regime) was 43 years, (SD 13 years)
- Proportion of females was 34% (53/155). The prescription of raltegravir by year was: 2008, 1% (2/155); 2010, 2% (3/155); 2012, 9% (14/155); 2014, 23% (36/155) and 2016 41% (64/155).
- Indications for use of raltegravir were: virological failure, 56% (88/155); adverse effects to other ART medications, 15%(23/155); comorbidities 12% (19/155); use as part of a first-line regime 6% (10/155); GI intolerance to PIs-6% (9/155), and pregnancy, 4% (6/155).
- The median time of use of raltegravir was 73 weeks.
- Data were available for 108 patients to evaluate virological response: 79 (73%) had a viral load of <37 c/ml; 12 (11%) between 37 and <200c/ml, and 6 (5.5%), between 200 and <400c/ml. Our proportion of virological response was 90% (97/108). There were not discontinuations of raltegravir due to adverse effects.

DISCUSSION/CONCLUSIONS

- The use of raltegravir among patients at Hospital Guillermo Almenara is low; but increasing over time.
- In most cases, indications for use of raltegravir were consistent with the local standard.
- The proportion of patients responding adequately to a raltegravir-based regime is high.

BIBLIOGRAPHY

1. van Halsema C, Whitfield T, Lin N, Ashton K, Torkington A, Ustianowski A **Five years' real-life experience with raltegravir in a large HIV centre.** Int J STD AIDS. 2016 Apr;27(5):387-93.
2. Steigbigel RT, et al, BENCHMRK Study Teams . **Raltegravir with optimized background therapy for resistant HIV-1 infection.** N Engl J Med. 2008 Jul 24;359(4):339-54
3. Rockstroh JK, et al.; STARTMRK Investigators. **Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: final 5-year results from STARTMRK.** J Acquir Immune Defic Syndr. 2013 May 1;63(1):77-85

MATERIALS AND METHODS

- This is an observational, retrospective, transversal and longitudinal study. HIV-positive patients older than 15 years-old receiving a raltegravir-including combination between July 2008 and May 2017 were included. To determine virological success a minimum period of 24 weeks receiving raltegravir plus at least one measurement of HIV-viral load was required.

Figure 1. Cumulative frequency of raltegravir use HNGAI 2008-2017





Figure 2. Indications of RAL use HNGAI 2008-2017



Other members of the Almenara Hospital AIDS working group are: L. Gutiérrez, J Villena , L. Illescas, A Irey , J. Vega , J. Hidalgo , R. Castillo, P. Castro , J. Magallanes.